Sanofi (NASDAQ:SNY) Position Increased by Natixis Advisors LLC

Natixis Advisors LLC increased its stake in shares of Sanofi (NASDAQ:SNY) by 4.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,874,193 shares of the company’s stock after buying an additional 114,133 shares during the quarter. Natixis Advisors LLC owned about 0.11% of Sanofi worth $165,640,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. POM Investment Strategies LLC bought a new position in shares of Sanofi during the second quarter worth about $25,000. Northwest Investment Counselors LLC bought a new position in Sanofi in the 3rd quarter worth about $29,000. Concord Wealth Partners grew its position in Sanofi by 157.8% in the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after purchasing an additional 363 shares during the last quarter. Arrow Financial Corp acquired a new stake in shares of Sanofi in the second quarter valued at approximately $35,000. Finally, Fortitude Family Office LLC raised its holdings in shares of Sanofi by 708.6% during the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock valued at $43,000 after buying an additional 659 shares during the last quarter. 10.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Stock Up 0.3 %

Shares of SNY stock opened at $47.97 on Friday. Sanofi has a 1 year low of $45.22 and a 1 year high of $58.97. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The business’s fifty day moving average is $54.65 and its 200-day moving average is $52.19. The stock has a market cap of $121.74 billion, a PE ratio of 24.47, a price-to-earnings-growth ratio of 1.26 and a beta of 0.61.

Sanofi (NASDAQ:SNY) last released its earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The firm had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. During the same period in the previous year, the company earned $2.55 earnings per share. Sanofi’s revenue was up 12.3% compared to the same quarter last year. Equities analysts expect that Sanofi will post 4.27 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on SNY shares. Argus raised their target price on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, July 26th. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 7th. Finally, Citigroup raised shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Two research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Sanofi has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.